Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its underwritten public offering, issuing 17,400,000 shares of common stock at a price of $5.75 per share, aiming to raise $100 million. The offering proceeds are before the deduction of underwriting discounts, commissions, and expenses. Trevi has also provided underwriters with a 30-day option to purchase an additional 2,610,000 shares at the same price. The offering, managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor, is expected to close on or around June 5, 2025, pending customary closing conditions. The funds will support Trevi's ongoing development of Haduvio™, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough.